Research Progress of Androgen/Androgen Receptor Signaling Pathway in Hepatocellular Carcinoma
-
摘要:
肝细胞癌是一种高死亡率的原发性肝癌。在我国,男性肝细胞癌发病率与女性发病率之比为2:1~5:1。男性和女性在性激素通路方面的差异和雄激素/雄激素受体与HBV相互作用均可导致肝细胞癌发生性别差异。雄激素/雄激素受体致癌通路在肝细胞癌中的研究受到较大关注。本综述主要总结近年来雄激素/雄激素受体在肝细胞癌发病性别差异中致癌作用机制及其研究进展。
Abstract:Hepatocellular carcinoma (HCC) is a kind of primary liver cancer with a high mortality rate. In China, the incidence ratio in males to females with HCC is 2:1–5:1. The difference in sex hormone pathways between males and females and the interaction between androgen/androgen receptors and HBV can lead to an incidence difference between males and females with HCC. Hence, the androgen/androgen receptor oncogenic pathway in hepatocellular carcinoma has received considerable attention. This review mainly summarizes the recent research progress on the androgen/androgen receptor oncogenic pathway in hepatocellular carcinoma.
-
Key words:
- Androgen /
- Androgen receptor /
- Signaling pathway /
- Hepatocellular carcinoma
-
0 引言
食管癌是因消化道肿瘤死亡的主要原因之一,食管鳞状细胞癌(esophageal squamous cell carcinoma, ESCC)约占全球食管癌的90%[1],因早期症状不明显,确诊时大部分患者已处于进展期,失去最佳根治手术时机,根治性同步放化疗(concurrent chemoradiotherapy, CCRT)是进展期ESCC的主要治疗方案[2]。临床实践中放化疗后的急性不良反应(acute adverse reactions, AAR)仍然困扰着医师和患者,且AAR随剂量的积累而增加,以中晚期患者为著[3]。铂类化疗通常会引起以血液学毒性和胃肠道毒性为主的不同类型急性不良反应,≥3级AAR可导致剂量减少、治疗延迟甚至终止放化疗,从而疗效不佳[4]。因此,个体化治疗方案有利于平衡疗效和AAR,使更多的患者获益。ESCC同步放化疗前CT检查既可评估肿瘤临床分期,亦可定量评估骨骼肌等身体成分变化[5]。有研究[2-6]表明骨骼肌量减少与多种癌症生存期缩短及治疗时AAR增加相关,去脂肪身体成分(主要为骨骼肌量)存在差异,放化疗后AAR亦不同,且大多数进展期ESCC患者因吞咽困难、疼痛、全身炎性反应和代谢率增加存在不同程度的骨骼肌量减少等,但进展期ESCC放化疗前肌肉减少症相关身体成分与同步放化疗AAR的关系仍存在争议。Dijksterhuis等[6]认为食管癌治疗前骨骼肌密度降低、肥胖型肌少症与3~4级剂量限制性毒性有关,而Ota等[7]发现治疗前骨骼肌减少症与化疗相关AAR无关;本研究目的是探讨进展期ESCC患者放化疗前骨骼肌减少症相关的身体成分变化与AAR、生存率的相关性。
1 资料与方法
1.1 病例选择及一般资料
回顾性收集徐州市肿瘤医院2018年8月—2022年7月期间符合标准的患者。纳入标准:(1)经病理确诊且临床TNM分期Ⅱ期以上(AJCC第8版[2])、预行同步放化疗的进展期ESCC患者;(2)可检索到治疗前血清白蛋白及中性粒细胞与淋巴细胞比例,包括L3双侧横突层面的中上腹部CT、胸部CT;(3)美国东部肿瘤协作组评分标准≤2分且年龄 > 18岁,无主要器官功能障碍;排除肿瘤相关资料不全(如身高、体重、肿瘤治疗相关不良反应等)的患者。本研究通过徐州市肿瘤医院伦理委员会审批。
1.2 CT检查及身体成分测量
同步放化疗前所有患者行胸部及上腹部能谱CT扫描(美国GE,Discovery CT-750HD),并将图像传输至工作站(ADW4.7,美国),根据文献描述方法[8],采用半自动化手工测量,以腰3横突为标志,在连续两层轴位图像上测量骨骼肌[(包括腰肌、椎旁肌(竖脊肌、腰方肌)和腹壁肌(腹横肌、内外斜肌、腹直肌)]和脂肪组织的横截面积(人工勾画腹壁肌肉、皮下脂肪、内脏脂肪边界,骨骼肌以-29~190 HU、皮下脂肪及肌肉间脂肪以-190~-30 HU、内脏脂肪以-150~-50 HU为阈值,软件自动算出骨骼肌、皮下脂肪、内脏间脂肪体积,再除以5 mm层厚),取两次平均值为骨骼肌面积(total muscle area, TMA)、皮下脂肪面积、内脏间脂肪面积,同时测量腰大肌的CT值,再通过公式:骨骼肌指数(skeletal muscle index, SMI)=TMA(cm2)/身高2(m2)、无脂骨骼肌量(fat-free mass, FFM, kg)=6.06+0.3×TMA(m2)、无脂体指数(fat-free mass index, FFMI)(kg/m2)=总FFM/身高2(m2)、脂肪量(fat mass, FM)(kg)=11.2+0.042×L3(皮下脂肪+内脏间脂肪量)、脂肪指数(fat mass index, FMI)(kg/m2)=总FM/身高2(m2)[8],计算出SMI、FFMI、FMI;体表面积(body surface area, BSA)(m2)={[高度(cm)×体重(kg)]/3 600}1/2。以SMI < 55 cm2/m2(男)、SMI < 39 cm2/m2(女)为标准诊断肌肉减少症[8],本组病例分为肌少症组和非肌少症组。
1.3 治疗方案、急性不良反应评估
所有患者均接受三维适形调强放疗,参照食管造影、CT及胃镜显示食管癌病灶及阳性淋巴结情况勾画靶区,并适当修改邻近危险器官剂量,95%计划靶区处方剂量为56~64 Gy,1次/天,5次/周,1.8~2 Gy/次,28~32次完成,心脏、肺平均剂量分别≤30 Gy、15 Gy,脊髓最大剂量≤45 Gy。同步接受2周期FP方案化疗:5-Fu 450~500 mg/m2×5 d,顺铂25~30 mg/m2×(3~5)d;28 d为1周期;为消除混杂因素影响,对肌少症组和非肌少症组的1周期、2周期顺铂总剂量行统计学分析,结果显示肌少症组1周期、2周期顺铂总剂量分别为143.25(四分位数12.75)mg、142.50(四分位数14.75)mg和非肌少症组144.75(四分位数9.75)mg、143.00(四分位数10.13)mg,差异无统计学意义(Z=-1.140、-0.981, P=0.254、0.327)。
根据CTCAE5.0版评价血液系统AAR(0~4级)[9],美国RTOG急性放射损伤分级标准评价急性放射性肺炎(0~4级)、急性放射性食管炎(0~4级)[10]。
1.4 随访
通过查询电子病历或电话回访患者(或家属)或定期门诊复查,随访至食管癌进展或患者死亡或截止日期,以月作为随访单位,记录患者发生急性不良反应情况及生存情况。
1.5 统计学方法
数据分析采用SPSS25.0及Graph Pad Prism8.0.1软件包。Fisher' s精确检验或χ2检验分析数据在肌少症组和非肌少症组间的差异。S-W检验对连续性数据行正态分布检验,再用独立样本t检验分析符合正态分布数据(x±s)及非参数检验分析不符合正态分布数据(中位数(四分位数))在两组间的差异。单因素分析筛选出与≥3级AAR有统计学意义的变量,Logistic回归模型进一步分析其影响因素。Kaplan-Meier法计算生存率及Log rank检验比较两组间生存率的差异。α=0.05(双尾)为检验水准。
2 结果
2.1 食管鳞状细胞癌患者临床基本情况及身体参数分布
132例进展期ESCC患者(Ⅲ期35例、ⅣA期59例、ⅣB期38例)纳入本研究中,男93例、女39例,中位年龄64(四分位数6)岁,同步放化疗前65.9%(87/132)患者存在肌少症,中位年龄64(四分位数8)岁,34.1%(45/132)患者无肌少症,中位年龄64(四分位数9)岁;颈段及胸上段34例、胸中段51例、胸下段22例、食管胃交界处癌25例。FFMI与BSA呈中度相关(r=0.593, P < 0.001),见图 1。与非肌少症组相比,肌少症组SMI、BMI、FMI、FFMI和骨骼肌密度较低(P < 0.001、0.036、 < 0.001、0.001、0.026);但治疗前ECOG-PS、血清白蛋白、中性粒细胞淋巴细胞比值、肿瘤位置及临床分期在两组间比较差异均无统计学意义,见表 1。
表 1 进展期食管鳞癌患者的基本情况Table 1 Demographics of patients with advanced ESCC2.2 食管鳞状细胞癌同步放化疗期间急性不良反应发生、影响因素及治疗完成情况
132例进展期ESCC中,发生≥3级血液系统AAR为14例,≥3级放射性食管炎7例,≥3级放射性肺炎9例,4例同时发生≥3级血液系统AAR、放射性食管炎,2例同时发生≥3级血液系统AAR、放射性肺炎,1例同时发生≥3级放射性食管炎、放射性肺炎,最终23例发生≥3级总AAR,见表 2;与非肌少症组相比,肌少症组总AAR、血液系统AAR发生率高(P=0.045、0.034),见表 1。
表 2 进展期食管鳞状细胞癌同步放化疗急性不良反应情况Table 2 Acute adverse reactions in patients with advanced ESCC who received concurrent chemoradiotherapy单因素、多因素分析显示SMI、肌肉减少症、脂肪指数、骨骼肌密度、骨骼肌总面积、无脂体指数、放疗剂量是发生≥3级AAR的影响因素,见表 3。32例患者化疗减量或暂停治疗,其中20例因AAR严重而致治疗依从性下降,8例因家庭经济原因而放弃继续治疗,4例未说明原因而放弃治疗;肌少症组的治疗依从性低于非肌少症组(P=0.035),见表 1。
表 3 进展期食管鳞癌同步放化疗≥3级急性不良反应影响单、多因素分析Table 3 Univariate and multivariate analyses of influencing factors of grade ≥3 AAR in patients with advanced ESCC who received concurrent chemoradiotherapy2.3 食管鳞状细胞癌患者的生存结果
从2018年8月随访至患者死亡或至2022年7月,9例患者失访,失访率为6.82%,随访时间15.68(12.46)月。肌少症组生存率为22.98%(20/87)低于非肌少症组40.00%(18/45)(χ2=4.187, P=0.041)。肌少症组中位生存期[16.01(95%CI: 14.89~17.13)月]低于无肌少症组[19.27(95%CI: 14.45~24.09)月](χ2=5.326, P=0.021),见图 2A。发生≥3级AAR的中位生存期[14.86(95%CI: 11.30~18.42)月]低于0~2级AAR[16.67(95%CI: 14.91~18.43)月](χ2=5.470, P=0.019),见图 2B。在发生≥3级AAR患者中行分层分析发现,肌少症组中位生存期[12.13(95%CI: 10.15~14.11)月]低于无肌少症组[18.69(95%CI: 12.85~21.88)月](χ2=4.466, P=0.035),见图 2C。
图 2 132例进展期食管鳞状细胞癌的生存分析曲线Figure 2 Survival curves of 132 patients with advanced ESCCA: survival curves of patients with advanced ESCC with or without sarcopenia before concurrent chemoradiotherapy; B: survival curves of patients with advanced ESCC with grade≥3 or 1-2 AAR of concurrent chemoradiotherapy; C: survival curves of advanced ESCC patients with grade≥3 grade AAR and sarcopenia or non-sarcopenia.3 讨论
本研究结果显示,肌少症患者身体成分变化(骨骼肌密度减低、骨骼肌总面积减少、脂肪量增多)与发生≥3级AAR的风险相关。进展期ESCC患者BMI均≥18.5 kg/m2,他们面临的风险与BMI < 18.5 kg/m2的患者不同,因为他们可能已经存在骨骼肌消耗,但是往往又被正常或较大的体质量和脂肪组织所掩盖。目前临床实际工作中根据患者体表面积确定化疗药物剂量,这部分患者被注射的化疗药物剂量相对增加,因为在相同身高和体质量的患者中,其体表面积相等,注射的化疗药物相等,但是5-Fu和铂类化疗药(包括顺铂、奥沙利铂和卡铂)都是亲水药物,分布到脂肪体组织(主要为骨骼肌组织)中并进行分解代谢[5]。肌少症患者的骨骼肌量减少,导致单位体积骨骼肌内的化疗药物剂量增高,发生≥3级AAR的风险(主要为血液系统不良反应)可能会增加,肥胖型肌少症患者发生风险可能会更高。因此定量评估身体组成成分(尤其去脂肪骨骼肌量)可作为指导进展期ESCC患者个性化化疗药物剂量的补充因素,尤其肥胖型肌少症患者。
进展期ESCC患者放化疗前常规采用胸腹部CT检查评估肿瘤临床分期,本研究采用CT图像额外定量评估身体成分的变化具有高度客观性和可重复性,而且不增加患者辐射剂量及经济负担。如在L3双侧横突层面CT图像上以-190 HU~-30 HU为阈值测量肌肉间脂肪是评估肌肉脂肪变性的一种无创测量方法,与肌肉活检获得的肌肉内脂质含量相关性较好[11];肌肉CT值与肌肉密度具有良好相关性,肌肉密度越低反映肌肉内脂肪浸润越多[12];肌肉密度减低与肿瘤预后不良和生存率减低有关[13]。本组结果显示骨骼肌量减少、骨骼肌密度减低、脂肪增多是发生≥3级AAR的危险因素,肌少症和AAR同时存在的患者有生存期缩短的风险,与Ganju等[14]研究头颈部癌合并肌少症的结果相仿,发现37%头颈部癌合并肌少症接受放化疗后发生 > 1种AAR,以急性血液系统不良反应为著,45%的肌少症患者有化疗延迟、剂量减少或治疗中断,进一步导致生存期缩短。CT定量评估患者身体成分(骨骼肌密度、骨骼肌总面积、脂肪量)可成为临床营养护理过程的一部分,有利于及时发现肌少症患者,采取早期营养和体育运动等个体化的干预方案,遵守改良的运动计划有助于减轻骨骼肌消耗,有助于降低发生≥3级AAR的风险[5]。
本研究存在一定的局限性:因本研究采用回顾性设计,缺乏营养支持、体育锻炼和患者生活质量的信息,可能影响肌少症与≥3级AAR的关系;因本研究中≥3级的血液系统不良反应、放射性肺炎、放射性食管炎的患者数量较少,对其危险因素未单独进行统计学分析。此外,由于各种原因导致的食欲下降可能与≥3级AAR相互作用,未来研究需把治疗期间的食物摄入量、身体活动考虑在内。
综上所述,CT可额外定量评估人体身体组成成分,发现肌少症相关的身体成分(骨骼肌量总面积的减少、骨骼肌密度减低、脂肪增多)与发生≥3级急性不良反应风险相关,把其考虑到化疗药物给药剂量中,可降低进展期ESCC患者同步放化疗的急性不良反应的发生率、改善其预后。
Competing interests: The authors declare that they have no competing interests.作者贡献:王瑞华:论文构思、撰写、校对蔡仕良:论文撰写、校对柳东红:论文修改、校对陈宏森:论文校对曹广文:论文整体框架设计 -
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2] 曹毛毛, 李贺, 孙殿钦, 等. 全球肝癌2020年流行病学现状[J]. 中华肿瘤防治杂志, 2022, 29(5): 322-328. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL202205003.htm Cao MM, Li H, Sun DQ, et al. Global epidemiology of liver cancer in 2020[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2022, 29(5): 322-328. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL202205003.htm
[3] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLZD202102001.htm Liu ZC, Li ZX, Zhang Y, et al. Interpretation on the report of Global Cancer Statistics 2020[J]. Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi, 2021, 7(2): 1-13. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLZD202102001.htm
[4] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview[J]. Int J Cancer, 2021, 5. Online ahead of print.
[5] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[6] 查旭东, 刘文斌, 曹广文. 肝细胞癌发生及预后性别差异的相关危险因素[J]. 上海预防医学, 2017, 29(4): 253-256. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYI201704002.htm Zha XD, Liu WB, Cao GW, et al. Risk factors related to the sexual dimorphism in the incidence and prognosis of hepatocellular carcinoma[J]. Shanghai Yu Fang Yi Xue, 2017, 29(4): 253-256. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYI201704002.htm
[7] Salvi S, Bonafè M, Bravaccini S. Androgen receptor in breast cancer: a wolf in sheep's clothing? A lesson from prostate cancer[J]. Semin Cancer Biol, 2020, 60: 132-137. doi: 10.1016/j.semcancer.2019.04.002
[8] Aurilio G, Cimadamore A, Mazzucchelli R, et al. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications[J]. Cells, 2020, 9(12): 2653. doi: 10.3390/cells9122653
[9] Shen T, Wang W, Zhou W, et al. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT[J]. J Clin Invest, 2021, 131(4): e135465. doi: 10.1172/JCI135465
[10] Aurilio G, Cimadamore A, Mazzucchelli R, et al. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications[J]. Cells, 2020, 9(12): 2653. doi: 10.3390/cells9122653
[11] Jacob A, Raj R, Allison DB, et al. Androgen receptor signaling in prostate cancer and therapeutic strategies[J]. Cancers (Basel), 2021, 13(21): 5417. doi: 10.3390/cancers13215417
[12] Di Oto E, Biserni GB, Varga Z, et al. X chromosome gain is related to increased androgen receptor expression in male breast cancer[J]. Virchows Arch, 2018, 473(2): 155-163. doi: 10.1007/s00428-018-2377-2
[13] Venema CM, Bense RD, Steenbruggen TG, et al. Consideration of breast cancer subtype in targeting the androgen receptor[J]. Pharmacol Ther, 2019, 200: 135-147. doi: 10.1016/j.pharmthera.2019.05.005
[14] Li Y, Xu A, Jia S, et al. Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma[J]. Oncol Lett, 2019, 17(5): 4222-4228.
[15] Han Q, Yang D, Yin C, et al. Androgen receptor (AR)-TLR4 crosstalk mediates gender disparities in hepatocellular carcinoma incidence and progression[J]. J Cancer, 2020, 11(5): 1094-1103. doi: 10.7150/jca.30682
[16] Gerratana L, Basile D, Buono G, et al. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype[J]. Cancer Treat Rev, 2018, 68: 102-110. doi: 10.1016/j.ctrv.2018.06.005
[17] Özturan D, Morova T, Lack NA. Androgen receptor-mediated transcription in prostate cancer[J]. Cells, 2022, 11(5): 898. doi: 10.3390/cells11050898
[18] Elshan NGRD, Rettig MB, Jung ME. Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain[J]. Med Res Rev, 2019, 39(3): 910-960. doi: 10.1002/med.21548
[19] Brüggenwirth HT, Boehmer AL, Verleun-Mooijman MC, et al. Molecular basis of androgen insensitivity[J]. J Steroid Biochem Mol Biol, 1996, 58(5-6): 569-575. doi: 10.1016/0960-0760(96)00095-7
[20] Tan MHE, Li J, Xu HE, et al. Androgen receptor: structure, role in prostate cancer and drug discovery[J]. Acta pharmacol Sin, 2015, 36(1): 3-23. doi: 10.1038/aps.2014.18
[21] Wärnmark A, Treuter E, Wright APH, et al. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation[J]. Mol Endocrinol, 2003, 17(10): 1901-1909. doi: 10.1210/me.2002-0384
[22] Yu X, Yi P, Hamilton RA, et al. Structural insights of transcriptionally active, full-length androgen receptor coactivator complexes[J]. Mol Cell, 2020, 79(5): 812-823.e4. doi: 10.1016/j.molcel.2020.06.031
[23] 周鑫宇, 柳东红, 蔡仕良, 等. 乙型肝炎病毒X基因及其变异促肝细胞癌的作用机制[J]. 中国癌症防治杂志, 2022, 14(1): 8-14. https://www.cnki.com.cn/Article/CJFDTOTAL-ZAZF202201017.htm Zhou XY, Liu DH, Cai SL, et al. The mechanism of hepatitis B virus X gene and its mutation in promoting hepatocellular carcinoma[J]. Zhongguo Ai Zheng Fang Zhi Za Zhi, 2022, 14(1): 8-14. https://www.cnki.com.cn/Article/CJFDTOTAL-ZAZF202201017.htm
[24] Zhang H, Spencer K, Burley SK, et al. Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma[J]. Drug Discov Today, 2021, 26(6): 1539-1546. doi: 10.1016/j.drudis.2021.02.001
[25] Ouyang X, Feng L, Liu G, et al. Androgen receptor (AR) decreases HCC cells migration and invasion via miR-325/ACP5 signaling[J]. J Cancer, 2021, 12(7): 1915-1925. doi: 10.7150/jca.49200
[26] Shi L, Lin H, Li G, et al. Targeting Androgen Receptor (AR)→IL12A Signal enhances efficacy of sorafenib plus NK cells immunotherapy to better suppress HCC progression[J]. Mol Cancer Ther, 2016, 15(4): 731-742. doi: 10.1158/1535-7163.MCT-15-0706
[27] Lee SR, Lee YH, Yang H, et al. Sex hormone-binding globulin suppresses NAFLD-triggered hepatocarcinogenesis after menopause[J]. Carcinogenesis, 2019, 40(8): 1031-1041. doi: 10.1093/carcin/bgz107
[28] Bigsby RM, Caperell-Grant A. The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis[J]. Carcinogenesis, 2011, 32(8): 1162-1166. doi: 10.1093/carcin/bgr094
[29] Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice[J]. Clin Gastroenterol Hepatol, 2015, 13(12): 2140-2151. doi: 10.1016/j.cgh.2015.08.014
[30] Kosinska AD, Pishraft-Sabet L, Wu W, et al. Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models[J]. Hepatology, 2017, 66(1): 69-83. doi: 10.1002/hep.29155
[31] White DL, Tavakoli-Tabasi S, Kuzniarek J, et al. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males[J]. Hepatology, 2012, 55(3): 759-768. doi: 10.1002/hep.24618
[32] Yang WJ, Chang CJ, Yeh SH, et al. Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3beta kinase pathways[J]. Hepatology, 2009, 49(5): 1515-1524. doi: 10.1002/hep.22833
[33] Tian Y, Kuo CF, Chen WL, et al. Enhancement of hepatitis B virus replication by androgen and its receptor in mice[J]. J Virol, 2012, 86(4): 1904-1910. doi: 10.1128/JVI.06707-11
[34] Tian YE, Xie XU, Lin Y, et al. Androgen receptor in hepatocarcinogenesis: recent developments and perspectives[J]. Oncol Lett, 2015, 9(5): 1983-1988. doi: 10.3892/ol.2015.3025
[35] Pu R, Liu W, Zhou X, et al. The effects and underlying mechanisms of hepatitis B virus X gene mutants on the development of hepatocellular carcinoma[J]. Front Oncol, 2022, 12: 836517. doi: 10.3389/fonc.2022.836517
[36] Sun H, Yang W, Tian Y, et al. An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma[J]. Nat Commun, 2018, 9(1): 5214. doi: 10.1038/s41467-018-07402-8
[37] Lee S, Lee M, Kim JB, et al. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling[J]. Biochemical Biophys Res Commun, 2016, 473(4): 1247-1254. doi: 10.1016/j.bbrc.2016.04.049
[38] Wu Y, Zhang Y, Qin X, et al. PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma[J]. Pharmacol Res, 2020, 160: 105195. doi: 10.1016/j.phrs.2020.105195
[39] Pungsrinont T, Kallenbach J, Baniahmad A. Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer[J]. Int J Mol Sci, 2021, 22(20): 11088. doi: 10.3390/ijms222011088
[40] Zhang H, Li XX, Yang Y, et al. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma[J]. Hepatology, 2018, 67(6): 2271-2286. doi: 10.1002/hep.29715
[41] Tian H, Zhu X, Lv Y, et al. Glucometabolic reprogramming in the hepatocellular carcinoma microenvironment: cause and effect[J]. Cancer Manag Res, 2020, 12: 5957-5974. doi: 10.2147/CMAR.S258196
[42] Ma WL, Jeng LB, Lai HC, et al. Androgen receptor enhances cell adhesion and decreases cell migration via modulating β1-integrin-AKT signaling in hepatocellular carcinoma cells[J]. Cancer Lett, 2014, 351(1): 64-71. doi: 10.1016/j.canlet.2014.05.017
[43] Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J]. Pharmacol Ther, 2014, 142(2): 164-175. doi: 10.1016/j.pharmthera.2013.12.004
[44] Shorning BY, Dass MS, Smalley MJ, et al. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling[J]. Int J Mol Sci, 2020, 21(12): 4507. doi: 10.3390/ijms21124507
[45] Chen C, Wang G. Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy[J]. World J Hepatol, 2015, 7(15): 1964-1970. doi: 10.4254/wjh.v7.i15.1964
[46] Delire B, Stärkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications[J]. Eur J Clin Invest, 2015, 45(6): 609-623. doi: 10.1111/eci.12441
[47] Neuzillet C, Tijeras-Raballand A, De Mestier L, et al. MEK in cancer and cancer therapy[J]. Pharmacol Ther, 2014, 141(2): 160-171. doi: 10.1016/j.pharmthera.2013.10.001
[48] Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication[J]. Annu Rev Pharmacol Toxicol, 2007, 47: 263-292. doi: 10.1146/annurev.pharmtox.47.120505.105337
[49] Penning TM. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review[J]. Expert Opin Ther Pat, 2017, 27(12): 1329-1340. doi: 10.1080/13543776.2017.1379503
[50] Jansson AK, Gunnarsson C, Cohen M, et al. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer[J]. Cancer Res, 2006, 66(23): 11471-11477. doi: 10.1158/0008-5472.CAN-06-1448
[51] Wang B, Gu Y, Hui K, et al. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling[J]. Urol Oncol, 2018, 36(10): 472.e11-e472.e20. doi: 10.1016/j.urolonc.2018.07.005
[52] Zhu P, Feng R, Lu X, et al. Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma[J]. Aging (Albany NY), 2021, 13(3): 4138-4156.
[53] Song H, Yu Z, Sun X, et al. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling[J]. EBioMedicine, 2018, 35: 155-166. doi: 10.1016/j.ebiom.2018.08.043
[54] Feng H, Yu Z, Tian Y, et al. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients[J]. J Hepatol, 2015, 62(5): 1100-1111. doi: 10.1016/j.jhep.2014.11.040
[55] Wei Y, Renard CA, Labalette C, et al. Identification of the LIM protein FHL2 as a coactivator of beta-catenin[J]. J Biol Chem, 2003, 278(7): 5188-5194. doi: 10.1074/jbc.M207216200
[56] Tong Z, Li M, Wang W, et al. Steroid receptor coactivator 1 promotes human hepatocellular carcinoma progression by enhancing Wnt/β-Catenin signaling[J]. J Biol Chem, 2015, 290(30): 18596-18608. doi: 10.1074/jbc.M115.640490
[57] Xu J, Zheng L, Chen J, et al. Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals[J]. Cell Death Dis, 2017, 8(10): e3095. doi: 10.1038/cddis.2017.411
[58] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390. doi: 10.1056/NEJMoa0708857
[59] Kanda T, Yokosuka O. The androgen receptor as an emerging target in hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2015, 2: 91-99.
[60] Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen[J]. Hepatology, 2004, 40(6): 1361-1369. doi: 10.1002/hep.20474
[61] Wang SH, Yeh SH, Shiau CW, et al. Sorafenib action in hepatitis B virus X-activated oncogenic androgen pathway in liver through SHP-1[J]. J Natl Cancer Inst, 2015, 107(10): djv190. doi: 10.1093/jnci/djv190
-
期刊类型引用(3)
1. 王元坦,许艳芳,段广廷. 低温等离子联合鼻内镜在复发性鼻腔鼻窦恶性肿瘤治疗中的应用价值. 实用癌症杂志. 2025(03): 444-447 . 百度学术
2. 杨媛,钱伟军. CT、MRI在鼻腔鼻窦恶性肿瘤鉴别诊断中的准确性及影像学分析. 哈尔滨医药. 2024(05): 31-34 . 百度学术
3. 黄菊芳,张玉杰,李蓓,单林霞,张璐. 高亲和型酪氨酸蛋白激酶类受体和上皮性钙黏连蛋白与鼻腔鼻窦腺样囊性癌病理及预后的关系. 医药论坛杂志. 2024(20): 2203-2207+2212 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 1454
- HTML全文浏览量: 420
- PDF下载量: 1910
- 被引次数: 3